A randomized controlled clinical trial of intranasal versus subcutaneous midazolam for agitation in terminal illness (MinTU study)

March 22, 2026Palliative MedicineOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the effectiveness of intranasal versus subcutaneous midazolam in managing agitation among patients with terminal illness.
Randomized controlled trial design
Comparison between intranasal and subcutaneous midazolam
Participants experiencing agitation due to terminal illness
Effectiveness of intranasal midazolam demonstrated in managing agitation
Subcutaneous midazolam showed similar effectiveness
No significant differences found between the two administration routes

Answers are grounded in this paper and cite their sources.

Randomized controlled trial compares intranasal and subcutaneous midazolam for agitation in terminal illness, suggesting treatment effectiveness.

MinTU Study 173-01, Eudra CT No.: 2021-004789-36, DRKS ID: 00026775 (07.07.2022, https://drks.de/search/de/trial/DRKS00026775).

No takes yet. Share an insight, caveat, or question.

Hirschinger et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share